Company: MDCXW
Filing Date: 2025-03-07
Form Type: 253G1
Source: 0001062993-25-004966
Chunk: 242

Company: Medicus Pharma Ltd.
Filing Date: 2025-03-07
Form: 253G1
Chunk 242
---
The Company signed a 42-month lease agreement for office space of approximately 3,500 square feet in West Conshohocken, Pennsylvania. The lease commenced on January 1, 2024. Future minimum rent payments under this lease are approximately $434,000.

On January 18, 2024, the Company announced the listing of its common shares on the Frankfurt Stock Exchange, trading under the symbol "N46".

On January 25, 2024, the Company filed a final short form base shelf prospectus, which allows the Company to offer up to $50,000,000 of common shares, preferred shares, warrants, subscription receipts, debt securities, or units comprised of more than one of the foregoing securities, or any combination thereof, in all of the provinces and territories of Canada over a 25-month period.

<div align='center'>F-47</div>

Subsequent to December 31, 2023, the Company granted 125,000 share options at an exercise price of C$4.82.

On June 25, 2024, the Board of Directors approved the acceleration of vesting for all outstanding shares to June 25, 2024, resulting in the Company recognizing the remaining expense for share options outstanding immediately during the period ended June 30, 2024.

On May 3, 2024, the Company issued convertible notes (the "2024 Notes") in the principal amount of $5,172,500. The convertible notes accrued interest at the rate of 10% per annum. On June 28, 2024, all of the holders of the convertible notes elected to convert to common shares. The Company paid cash interest of $40,563 and accrued interest of $38,462 was converted, along with the principal amount of $5,172,500, into 1,308,798 common shares. Related parties consisting of key management personnel subscribed for 168,750 of the 2024 Notes, in the principal amount of $675,000. Upon conversion the Company issued 172,953 common shares to related parties.

On June 28, 2024, the Company issued 1,461,250 common shares as part of a private placement for total proceeds of $5,845,000 at $4.00 per common share. The company incurred finders' fees of $375,000, which was recognized in equity as deduction from the gross proceeds received.

On October 28, 2024, the